Jul 13, 2010 - tiometry (DXA) at the level of lumbar spine L2-L4 (BMD L2-L4) and femoral neck (BMD-Fn). Results: MS patients had higher plasma visfatin ...
J. Endocrinol. Invest. 34: e12-e15, 2011 DOI: 10.3275/7170
Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome G. Iacobellis1, M. Iorio2, N. Napoli3, D. Cotesta2, L. Zinnamosca2, C. Marinelli2, L. Petramala2, S. Minisola2, E. D’Erasmo2, and C. Letizia2 1Endocrinology 2Department
Division, Department of Medicine, McMaster University, Hamilton, ON, Canada; of Clinical Sciences, Sapienza University; 3Endocrinology, Campus Biomedico University, Rome, Italy
ABSTRACT. Background: Adipose tissue has been suggested to influence bone density and metabolism through the effect of some adipokines. However, whether adiponectin and visfatin may correlate with bone metabolism is still unclear. Aim: The aim of this study was to investigate the relationship of adiponectin and visfatin with bone density in patients with metabolic syndrome (MS). Subjects: We enroled 72 consecutive patients with MS (25 males, 47 females; mean age 58.14±11 yr) and 40 control subjects. Methods: Plasma adiponectin and visfatin levels were measured. Bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry (DXA) at the level of lumbar spine L2-L4 (BMD L2-L4)
and femoral neck (BMD-Fn). Results: MS patients had higher plasma visfatin and lower adiponectin levels than controls, (p
